These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 9548450)

  • 1. Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas.
    Kakehi Y; Ozdemir E; Habuchi T; Yamabe H; Hashimura T; Katsura Y; Yoshida O
    Jpn J Cancer Res; 1998 Feb; 89(2):214-20. PubMed ID: 9548450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strong correlation of basement membrane degradation with p53 inactivation and/or MDM2 overexpression in superficial urothelial carcinomas.
    Ozdemir E; Kakehi Y; Okuno H; Habuchi T; Okada Y; Yoshida O
    J Urol; 1997 Jul; 158(1):206-11. PubMed ID: 9186361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles of p53 and MDM2 in tumor proliferation and determination of the prognosis of transitional cell carcinoma of the renal pelvis and ureter.
    Hashimoto H; Sue Y; Saga Y; Tokumitsu M; Yachiku S
    Int J Urol; 2000 Dec; 7(12):457-63. PubMed ID: 11168685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy.
    Kim KH; Do IG; Kim HS; Chang MH; Kim HS; Jun HJ; Uhm J; Yi SY; Lim DH; Ji SH; Park MJ; Lee J; Park SH; Kwon GY; Lim HY
    APMIS; 2010 Dec; 118(12):941-8. PubMed ID: 21091775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of p53 and mdm2 and their significance in recurrence of superficial bladder cancer.
    Tuna B; Yörükoğlu K; Tüzel E; Güray M; Mungan U; Kirkali Z
    Pathol Res Pract; 2003; 199(5):323-8. PubMed ID: 12908522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of p53, MDM2 and bcl-2 expression in transitional cell carcinoma of the bladder.
    Uchida T; Minei S; Gao JP; Wang C; Satoh T; Baba S
    Oncol Rep; 2002; 9(2):253-9. PubMed ID: 11836589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p21 and p53 Immunostaining and survival following systemic chemotherapy for urothelial cancer.
    Jankevicius F; Goebell P; Kushima M; Schulz WA; Ackermann R; Schmitz-Dräger BJ
    Urol Int; 2002; 69(3):174-80. PubMed ID: 12372883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters.
    Haitel A; Wiener HG; Baethge U; Marberger M; Susani M
    Clin Cancer Res; 2000 May; 6(5):1840-4. PubMed ID: 10815906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors.
    Günther T; Schneider-Stock R; Rys J; Niezabitowski A; Roessner A
    J Cancer Res Clin Oncol; 1997; 123(7):388-94. PubMed ID: 9260591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
    Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
    Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of multidrug resistance gene product (P-glycoprotein) in transitional cell carcinomas of the upper urinary tract.
    Shinohara N; Nonomura K; Takakura F; Hamada M; Grossman HB; Koyanagi T
    Eur Urol; 1994; 26(4):327-33. PubMed ID: 7713132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review.
    Aziz A; Dobruch J; Hendricksen K; Kluth LA; Necchi A; Noon A; Rink M; Roghmann F; Seiler R; Gontero P; Kassouf W; Shariat SF; Xylinas E;
    World J Urol; 2017 Sep; 35(9):1401-1407. PubMed ID: 28074261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations affecting the p53 control pathway in bilharzial-related bladder cancer.
    Osman I; Scher HI; Zhang ZF; Pellicer I; Hamza R; Eissa S; Khaled H; Cordon-Cardo C
    Clin Cancer Res; 1997 Apr; 3(4):531-6. PubMed ID: 9815716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncologic outcomes obtained after neoadjuvant and adjuvant chemotherapy for the treatment of urothelial carcinomas of the upper urinary tract: a review.
    Cordier J; Sonpavde G; Stief CG; Tilki D
    World J Urol; 2013 Feb; 31(1):77-82. PubMed ID: 23053212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Molecular biological testing for diagnosis and treatment of urothelial cancer].
    Kakehi Y
    Hinyokika Kiyo; 1999 Aug; 45(8):583-8. PubMed ID: 10500967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The expression of p53 and c-erb-2 in transitional cell carcinoma of the kidney pelvis and ureter and its relation to tumor progression and survival].
    Fontana LO; García García F; Arcas Martínez Salas I; García Ligero J; Tomás Ros M; Rico Galiano JL; Sempere Gutiérrez A; Canteras Jordana M
    Arch Esp Urol; 2002 Sep; 55(7):792-6. PubMed ID: 12380307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma.
    Siu LL; Banerjee D; Khurana RJ; Pan X; Pflueger R; Tannock IF; Moore MJ
    Clin Cancer Res; 1998 Mar; 4(3):559-65. PubMed ID: 9533522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of clinical outcome with p53 and p21 status in patients with advanced transitional-cell carcinoma treated with paclitaxel and carboplatin.
    Flamm M; Brodowicz T; Haitel A; Susani M; Tomek S; Köstler W; Pycha A; Kratzik C; Marberger M; Zielinski CC
    Anticancer Res; 2002; 22(2B):1295-300. PubMed ID: 12168940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 and MDM2 in the development and progression of bladder cancer.
    Schmitz-Dräger BJ; Kushima M; Goebell P; Jax TW; Gerharz CD; Bültel H; Schulz WA; Ebert T; Ackermann R
    Eur Urol; 1997; 32(4):487-93. PubMed ID: 9412812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC.
    Sarkis AS; Bajorin DF; Reuter VE; Herr HW; Netto G; Zhang ZF; Schultz PK; Cordon-Cardo C; Scher HI
    J Clin Oncol; 1995 Jun; 13(6):1384-90. PubMed ID: 7751883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.